Get an email when this journal's indexing changes
Added to or removed from Scopus, Web of Science, ABDC, DOAJ, FT50, UT Dallas or ONOS. One confirmation click; unsubscribe anytime.
Current Enzyme Inhibition is Scopus-indexed (Q4, CiteScore 1.5). It is covered by India's One Nation One Subscription scheme for reading access. Published by Bentham Science Publishers.
Checked against the index lists dated .
ISSN 1573-4080Verify ISSN ↗1875-6662Verify ISSN ↗
Publisher: Bentham Science Publishers
Cost to publish: No APC data — check the publisher
| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Biochemistry | 378 / 448 | 15th | Q4 |
| Drug Discovery | 139 / 161 | 13th | Q4 |
| Molecular Medicine | 160 / 179 | 10th | Q4 |
Not listed in: Web of Science, DOAJ, ABDC, ABS / AJG, FT50, UT Dallas, ONOS (APC covered)
Yes — actively indexed in Scopus, coverage 2006–present, best quartile Q4, CiteScore 1.5.
Current Enzyme Inhibition is Q4 in Biochemistry (rank 378 of 448), Q4 in Drug Discovery (rank 139 of 161) and Q4 in Molecular Medicine (rank 160 of 179), by CiteScore 2025.
Current Enzyme Inhibition is not in the Web of Science Core Collection (SCIE, SSCI, AHCI or ESCI), so Clarivate publishes no Journal Impact Factor for it. Its Scopus CiteScore is 1.5, quartile Q4, 15th percentile. Any "impact factor" quoted elsewhere is not the Clarivate metric. Its SCImago Journal Rank (SJR, a free Scopus-based metric) is 0.242, quartile Q4, with an H-index of 21.
Current Enzyme Inhibition is published by Bentham Science Publishers. Its print ISSN is 1573-4080 and its online ISSN is 1875-6662.
Yes. It is part of the One Nation One Subscription (ONOS) national subscription, so readers at participating Indian institutions get its full text. ONOS does not cover its article processing charge.
No — it is not currently in the Web of Science core collections (SCIE, SSCI, AHCI or ESCI).
No — it is not registered as an open-access journal in DOAJ or Scopus.
Current Enzyme Inhibition has an h-index of 23 and a 2-year mean of 0.47 citations per paper (OpenAlex). Its Scopus CiteScore is 1.5, quartile Q4. On 2-year citations it ranks #392 of 442 Scopus journals in Biochemistry.
Current Enzyme Inhibition published 41 papers in 2025. 2026* is the year so far.
h-index, i10-index and 2-year mean citedness are open, licence-clear metrics from OpenAlex — not a proprietary impact factor. The subject rank counts only journals that OpenAlex has a figure for; it is not a Scopus or Clarivate ranking. Updated 2026-10-14.
In its latest 99 research articles (2023–2026), authors are most often from India (64.8%), Algeria (5.1%) and Nigeria (2.5%). More than half of recent authorship comes from one country.
Countries are counted fractionally, so a paper by authors from two countries counts half to each.
Scopus status: Active. No retracted papers are recorded. The Problematic Paper Screener flags 1 of its papers. These are indicators to check, not findings against the journal.
Retractions from OpenAlex; flags from the Problematic Paper Screener (Cabanac, Labbé & Magazinov, CC BY), 2026-09-21 export. A flag marks a paper for a closer look; it is not a finding against the journal.
Index data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.
Comments load as you scroll here.